Chinese Biotech Firm Immunochina Raises $20M In Series C Round

Login to View

Chinese biotechnology company Immunochina Pharmaceuticals has raised a RMB$140 million (US$20.4 million) series C round of financing led by a syndicate of Chinese and international investors, according to a statement released on January 22.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in